DPP4 and fatty liver disease: Recent evidence in mice demonstrated that dipeptidyl peptidase-4 (DPP-4) inhibitors could improve the degree of hepatic steatosis and IR through AMPK-dependent and JNK-dependent inhibition of LECT2 expression[41].